Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study

Acta Haematol (2015) 135 (1): 29–36.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Katharina Kriegsmann
Max Bittrich
Sandra Sauer
Carola Tietze-Stolley
Kamran Movassaghi
Matthias Grube
Vladan Vucinic
Daniela Wehler
Andreas Burchert
Martin Schmidt-Hieber
Andreas Rank
Heinz A. Dürk
Bernd Metzner
Christoph Kimmich
Marcus Hentrich
Christian Kunz
Frank Hartmann
Cyrus Khandanpour
Maike de Wit
Udo Holtick
Michael Kiehl
Andrea Stoltefuß
Alexander Kiani
Ralph Naumann
Christian W. Scholz
Hans-Joachim Tischler
Martin Görner
Franziska Brand
Martin Ehmer
Nicolaus Kröger

Transfusion Medicine and Hemotherapy (2023) 50 (5): 403.

Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts

Leona A. Holmberg
Michael Linenberger
Laura Connelly-Smith

Transplantation and Cellular Therapy (2022) 28 (11): 754.

Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

Ivetta Danylesko
Rina Sareli
Nira Varda-Bloom
Ronit Yerushalmi
Noga Shem-Tov
Hila Magen
Avichai Shimoni
Arnon Nagler

International Journal of Hematology (2021) 114 (3): 363.

The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience

Girish Badarkhe
Radheshyam Naik

Indian Journal of Medical and Paediatric Oncology (2020) 41 (04): 530.

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability

Fotios V. Michelis
David W. Hedley
Sonal Malhotra
Sue Chow
David Loach
Vikas Gupta
Dennis D. Kim
John Kuruvilla
Jeffrey H. Lipton
Auro Viswabandya
Hans A. Messner

Biology of Blood and Marrow Transplantation (2019) 25 (6): 1158.

The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review

Hadrien Golay
Simona Jurkovic Mlakar
Vid Mlakar
Tiago Nava
Marc Ansari

International Journal of Molecular Sciences (2019) 20 (16): 3889.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report

Ivana N. Micallef
Patrick J. Stiff
Auayporn P. Nademanee
Richard T. Maziarz
Mitchell E. Horwitz
Edward A. Stadtmauer
Jonathan L. Kaufman
John M. McCarty
Rita Vargo
Peter D. Cheverton
Martin Struijs
Brian Bolwell
John F. DiPersio

Biology of Blood and Marrow Transplantation (2018) 24 (6): 1187.

CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma

Thomas A Werner
Christina M Forster
Levent Dizdar
Pablo E Verde
Katharina Raba
Matthias Schott
Wolfram T Knoefel
Andreas Krieg

British Journal of Cancer (2017) 117 (12): 1837.

Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean

A Olivieri
F Saraceni

Bone Marrow Transplantation (2016) 51 (3): 348.